ObsEva SA (OBSV)

7.38
NASDAQ : Health Technology
Prev Close 7.68
Day Low/High 7.38 / 7.85
52 Wk Low/High 7.14 / 17.99
Avg Volume 47.10K
Exchange NASDAQ
Shares Outstanding 43.72M
Market Cap 335.77M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ObsEva SA To Participate In Cantor Global Healthcare Conference October 2-4, 2019

ObsEva SA To Participate In Cantor Global Healthcare Conference October 2-4, 2019

Geneva, Switzerland and Boston, MA - September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a...

Relative Strength Alert For ObsEva

Relative Strength Alert For ObsEva

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ObsEva Announces New Composition Of Its Executive Committee

ObsEva Announces New Composition Of Its Executive Committee

Geneva, Switzerland and Boston, MA - September 11, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise...

ObsEva Reports New Clinical Evidence Of Nolasiban Mechanism Of Action, Supporting Its Potential To Increase Live Birth Rate Following Embryo Transfer In IVF

ObsEva Reports New Clinical Evidence Of Nolasiban Mechanism Of Action, Supporting Its Potential To Increase Live Birth Rate Following Embryo Transfer In IVF

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva's novel oxytocin receptor antagonist...

ObsEva SA To Participate In Upcoming Investor Conferences

ObsEva SA To Participate In Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA - August 30, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's...

ObsEva SA To Participate In Wedbush PacGrow Healthcare Conference August 13-14, 2019

ObsEva SA To Participate In Wedbush PacGrow Healthcare Conference August 13-14, 2019

Geneva, Switzerland and Boston, MA - August 9, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's...

ObsEva Reports Second Quarter 2019 Financial Results

ObsEva Reports Second Quarter 2019 Financial Results

  Multiple Major Milestones Expected This Year-    Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban  -    Nolasiban MAA submission targeted for year- end 2019-    Q4:19 Phase 3 data for PRIMROSE 2 trial of linzagolix in uterine fibroids     GENEVA,...

ObsEva SA Announces $75 Million Credit Facility With Oxford Finance LLC

ObsEva SA Announces $75 Million Credit Facility With Oxford Finance LLC

  Geneva, Switzerland and Boston, MA - August 7, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a...

ObsEva SA To Hold Second Quarter 2019 Financial Results And Business Update Call On August 7, 2019

ObsEva SA To Hold Second Quarter 2019 Financial Results And Business Update Call On August 7, 2019

  Geneva, Switzerland and Boston, MA - August 5, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a...

ObsEva SA Reports Positive Feedback From Independent Data Monitoring Committee For PROLONG Part B With OBE022

ObsEva SA Reports Positive Feedback From Independent Data Monitoring Committee For PROLONG Part B With OBE022

Geneva, Switzerland and Boston, MA - July 26, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's...

ObsEva To Increase Issued Share Capital By Creating Additional Treasury Shares

ObsEva To Increase Issued Share Capital By Creating Additional Treasury Shares

Geneva, Switzerland and Boston, MA - July 18, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a...

ObsEva Hosts KOL Meeting On IVF Trends, Unmet Need And Market Potential Of Nolasiban

ObsEva Hosts KOL Meeting On IVF Trends, Unmet Need And Market Potential Of Nolasiban

                                         Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019   GENEVA, Switzerland and BOSTON, MA -  July 17, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical...

ObsEva SA To Host Key Opinion Leader Meeting On In Vitro Fertilization (IVF) July 17, 2019 In New York City

ObsEva SA To Host Key Opinion Leader Meeting On In Vitro Fertilization (IVF) July 17, 2019 In New York City

Geneva, Switzerland and Boston, MA - July 12, 2019- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive...

ObsEva SA Announces Completion Of Patient Recruitment In PRIMROSE 1 Phase 3 Clinical Trial Of Linzagolix For The Treatment Of Heavy Menstrual Bleeding Associated With Uterine Fibroids

ObsEva SA Announces Completion Of Patient Recruitment In PRIMROSE 1 Phase 3 Clinical Trial Of Linzagolix For The Treatment Of Heavy Menstrual Bleeding Associated With Uterine Fibroids

Geneva, Switzerland and Boston, MA - July 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's...

RSI Alert: ObsEva Now Oversold

RSI Alert: ObsEva Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABM, ACBI, INTL, KMI, MRT, THS Downgrades: COST, DCUD, HALL, OBSV Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

ObsEva Enters Oversold Territory (OBSV)

ObsEva Enters Oversold Territory (OBSV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OBSV Downgrades: BGS, BLDP, CIO, NLY, PRTY, SRLP, TNC, WELL Initiations: ROYT Read on to get TheStreet Quant Ratings' detailed report:

Relative Strength Alert For ObsEva

Relative Strength Alert For ObsEva

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: None Downgrades: CA, CJ, CUO, ICCC, SCM Initiations: OBSV Read on to get TheStreet Quant Ratings' detailed report:

Oversold Conditions For ObsEva (OBSV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D (Sell)